Rocket Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rocket Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Rocket Pharmaceuticals: 10 sponsored US clinical trials, 5 recruiting.
Rocket Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Danon Disease, with 2 trials.
Top-decile sponsor footprint
Rocket Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy
NCT07137338
PKP2-ACM Natural History Study
NCT06644742
Danon Disease Natural History Study
NCT06214507
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
NCT06092034
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
NCT05885412
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
NCT06282432
Gene Therapy for Fanconi Anemia, Complementation Group A
NCT04248439
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis
NCT04525352
Gene Therapy for Pyruvate Kinase Deficiency (PKD)
NCT04105166
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
NCT03812263
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
What is open in the Rocket Pharmaceuticals pipeline
5 recruiting of 10 indexed (50% open); 2 completed (20%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Danon Disease (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rocket Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 10 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Rocket Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Rocket Pharmaceuticals page
10 registered trials is a research-attention snapshot, not an endorsement of Rocket Pharmaceuticals or any single study.
- 5 of Rocket Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Danon Disease is the condition Rocket Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Danon Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rocket Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.